Health care stocks were retreating Friday afternoon, with the NYSE Health Care Index down 0.1% and the Health Care Select Sector SPDR Fund (XLV) 0.2% lower.
The iShares Biotechnology ETF (IBB) fell 1.9%.
In corporate news, Eli Lilly (LLY) said Friday that data from its open-label extension study showed bowel disease drug Omvoh provided long-term clinical remission and endoscopic response to people with Crohn's disease as well as for those with prior biologic failure. Its shares rose 1.6%.
Illumina (ILMN) shares fell 8.2% after the company posted overnight lower Q4 revenue.
Ascentage Pharma (AAPG) said Friday that underwriters of its US initial public offering have partially exercised an over-allotment option to buy an additional 935,144 American depositary shares at the IPO price of $17.25 per ADS. Its shares shed 0.8%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.